Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-Month Parallel Group, Double-Blind, Randomised, Placebo-Controlled Study.
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2009
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SAFE-Portugal
- 09 Jan 2008 Status changed from in progress to completed.
- 21 Nov 2005 New trial record.